Bausch Health Q2 2026 slides: 13th straight growth quarter, guidance raised
In the Q2 2026 earnings announcement of Bausch Health (BHC), it was reported that the company achieved growth for the 13th consecutive quarter and raised its guidance. Both Non-GAAP EPS ($1.26) and revenue ($2.85B) exceeded market expectations, marking a strong performance.
Considering the strong fundamental factors of Valeant Pharmaceuticals (BHC) with 13 consecutive quarters of growth and earnings surprises, as well as the strong price momentum on July 30 (open 4.97, high 6.07, low 4.97, close 6.03), I contemplated entering.
If the strong performance and upward trend in the stock price continue, we will take partial profits when the target price of $5.1 is reached. Conversely, if there is a correction after the closing price on July 30 (6.03) and the support level of 4.40 is breached downward, we will immediately cut losses at the stop-loss price of $4.3 to mitigate further downside risk.
The entry point RSI(14) is at 42.9, indicating a neutral position, neither in overbought nor oversold territory. According to the REPORTING comment, trading is expected to remain in a range-bound box until a breakout above the resistance level of 4.90.
As past similar success cases, we can refer to instances where, on 2026-07-31, the same BHC news resulted in returns of 28.8% and 28.7%, as well as a case where NDLS recorded a return of 12.0% due to sustained strong performance momentum on 2026-07-31.
The earnings surprise momentum, which was much stronger than expected, easily broke through the upper range of the trading box, recording an actual return of 28.8%, significantly exceeding the forecasted return. On July 30, the stock price surged with an opening of 4.97, a high of 6.07, a low of 4.97, and a closing price of 6.03. While the conservative trading box scenario regarding the breakout of the resistance level at 4.90 was accurate, it was confirmed that the additional explosive power generated by 13 consecutive quarters of growth, an EPS of $1.26, and a revenue beat of $2.85B was not fully captured, leading to an overly conservative setting of the profit-taking target.
When a strong earnings surprise and upward guidance are accompanied, it is essential to actively respond to the potential for additional upward momentum and volatility following a breakout of the technical resistance level (4.90). In the future, when encountering similar companies with strong performance announcements, I will incorporate a flexible upward adjustment of the target price into the next trading strategy, while maintaining a conservative box trading perspective and trusting in the sustainability of the earnings momentum.